NAME POSITION TITLE
Myra L. Muramoto, MD, MPH Associate Professor
eRA Commons User Name (credential, e.g., agency login)
INSTITUTION AND LOCATION DEGREE YEAR(s) FIELD OF STUDY
University of Arizona, Tucson, AZ BS 1981 Nutritional Science
University of Arizona, Tucson, AZ MD 1985 Medicine
University of Arizona, Tucson, AZ 1988 Family Medicine
University of Arizona, Tucson, AZ MPH 1999 Epidemiology
Program in Integrative Medicine, University of 2005 Integrative Medicine
Arizona, Tucson, AZ
A. Personal Statement
B. POSITIONS AND HONORS
Appointments and positions
1990-1994 Clinical Assistant Professor of Family and Community Medicine, University of Arizona
1990-1992 Assoc. Medical Director for Medical Education/Research, Sierra Tucson Center for Addictions
1992-1993 Chief of Party/Project Manager, Lesotho Highland Health Survey, Lesotho, Africa:
Baseline epidemiological survey for site of a multi-phase water development project, one of the
largest heavy construction projects in the world
1994-1997 Assistant Professor of Clinical Family and Community Medicine, University of Arizona
1994-2000 Medical Director and/or Co-Investigator, Arizona Program for Nicotine and Tobacco Research.
Multiple studies of pharmacological and behavioral treatments for smoking cessation
1997-2003 Assistant Professor of Family and Community Medicine, University of Arizona
1997-2003 Assistant Professor of Public Health, University of Arizona
2003-2010 Associate Professor (tenured) of Family and Community Medicine, University of Arizona
2003- Associate Professor of Public Health, University of Arizona
2006- Founding Director, University Physicians Healthplan tobacco Dependence Treatment Program
2010- Professor of Family and Community Medicine (effective July 1, 2010), University of Arizona
Other Relevant Experience and Professional Associations (Selected):
1998- Society for Nicotine and Tobacco Research, Member
2000- American Academy of Pediatrics Child Health Research Center Tobacco Consortium
2000-2001 American Legacy Foundation, Emerging Science Advisory Panel
2001 American Legacy Foundation, Advisory Committee on Helplines for Pregnant Smokers
2001-2003 Consultant to World Bank Group on tobacco cessation projects in Indonesia, Romania
2002-2005 Scientific Advisory Group, Maine Tobacco Treatment Initiative
2003,2005 California Tobacco-Related Disease Research Program, Social and Participatory Research
2005 National Heart Lung and Blood Institute R18 Review Committee, Member
2005 Center for Medicare Services Expert Panel on Tobacco Dependence Treatment, Member
2005-2007 Robert Wood Johnson Foundation, Consumer Demand Expert Roundtable
2006-2009 National Institute of Drug Abuse, Treatment Research Review Subcommittee, Charter Member
2006- Scientific Advisory Committee, American Academy of Pediatrics, Richmond Center of
Excellence on Children
2007 Pennsylvania Dept. of Health, Improving Tobacco Dependence Treatment, Grant reviewer
2010 NIH National Center for Research Resources, Institutional Clinical Translational Science Award
(CTSA) Review Committee, Member
1996-2009 Selected for The Best Doctors in America, 1996 through 2009
2002 Election to Alpha Nu Chapter of Delta Omega, National Public Health Honorary Society
2005 American Medical Women’s Association Local Legends Award
2008 University of Arizona Asian American Faculty, Staff and Alumni Association
Outstanding Faculty Award
C. SELECTED PEER-REVIEWED PUBLICATIONS: (selected from 39 peer-reviewed publications)
1. Leischow SJ, Muramoto ML, Cook GN, Merikle EP, Castellini SM, Otte PS. OTC Nicotine Patch: Alone and with
brief physician intervention. American Journal of Health Behavior. 1999;23(1):61-69.
2. Jorenby DJ, Leischow SJ, Nides MA, Rennard SI, Johnson JA, Hughes AR, Smith SS, Muramoto ML, Daughton
DM, Doan K, Fiore MC, Baker TB. Effect of sustained release bupropion, a nicotine patch, or their combination for
smoking cessation. New England Journal of Medicine. 1999;340(9): 685-691.
3. Muramoto ML, Connolly T, Strayer LJ., Ranger-Moore J, Blatt W*, Leischow R, Leischow S. Tobacco
Cessation Skills Certification in Arizona: Application of a Statewide, Community-based Model for Diffusion of
Evidence-based Practice Guidelines. Tobacco Control. 2000;9 (4);408-414.
4. Muramoto ML, Ranger-Moore J, Leischow SJ, Efficacy of Oral Transmucosal Nicotine Lozenge for Suppression of
Withdrawal Symptoms. Nicotine and Tobacco Research. 2003;5(2):223-230.
5. Pbert L, Moolchan ET, Muramoto ML, Winickoff JP, Curry S, Lando H, Ossip-Klein D, Prokhorov AV, DiFranza J,
Klein JD. The State of Office-based Interventions for Youth Tobacco Use. Pediatrics. 2003;111:e650-660.
6. Leischow S, Ranger-Moore J, Muramoto ML, Matthews E. Effectiveness of the Nicotine Inhaler for Smoking
Cessation in an OTC Setting. American Journal of Health Behavior. 2004;28 (4):291- 301.
7. Nichter M, Nichter M, Muramoto ML, Adrian S, Goldade K, Thompson J, Tessler L. Smoking among Low Income
Pregnant Women: An Ethnographic Analysis. Health Education and Behavior. 2007; 34:748-764.
8. Shoham V, Rohrbaugh MJ, Trost SE, Muramoto ML. A family consultation (FAMCON) intervention for health-
compromised smokers. Journal of Substance Abuse Treatment. 2006; 31:395- 402.
9. Campbell J, Mays MZ, Yuan NP, Muramoto ML. Who are Health Influencers? Characterizing a sample of tobacco
cessation interveners. American Journal of Health Behavior. 2007; 31(2):181-192.
10. Muramoto ML, Leischow SJ, Sherrill D, Matthews E, Strayer L. A randomized, double-blind, placebo-controlled
trial of two doses of sustained release bupropion of adolescent smoking cessation. Archives of Pediatric and
Adolescent Medicine. 2007;161(11):1068-1074.
11. Castañeda H, Nichter M, Nichter M, Muramoto ML. Enabling and Sustaining the Activities of Lay Health
Influencers: Lessons from a Community-Based Tobacco Cessation Intervention Study. Health Promotion Practice.
2008; vol.0: pp. 1523839908318288v1.
12. Muramoto ML, Lando HA. Faculty Development in Tobacco Cessation: Training Health Professionals and
Promoting Tobacco Control in Developing Countries. Drug and Alcohol Review. 2009; (September); 28:498-506.
13. Yuan NP, Wind S, Nichter M, Nichter M, Castañeda H, Carruth L, Muramoto ML. Types of Lay Health Influencers
in Tobacco Cessation: A Qualitative Study. American Journal of Health Behavior. 2010; 34(5): 607-617.
14. Muramoto ML, Wassum K, Connolly T, Matthews E, Ford L. Helpers Program: A Pilot Test of Brief Tobacco
Intervention Training in Three Corporations. American Journal of Preventive Medicine. 2010; 38(3S):s319-s326.
15. Ng N, Nichter M, Padmawati RS, Prabandari YS, Muramoto ML, Nichter M. Bringing smoking cessation to diabetes
clinics in Indonesia. Chronic Illness (in press).
D. RESEARCH SUPPORT
Ongoing Research Support (selected)
NIH/NCI 1R01CA137375-01A1 (PI: Muramoto) (7/1/09 – 5/30/2014)
Tobacco Cessation Training for Acupuncture, Massage, & Chiropractic Practitioners
The major purpose of this project is to address a pressing need to develop and test the effectiveness of
cessation training that is grounded in guideline-based treatment and that is relevant and appropriate for CAM
NABI Biopharmaceuticals (PI Leischow) (12/31/09 – 1/1/11)
A Phase 3, Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Efficacy and
Safety of 3 aminiomethylnicotine-P aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to
Smoking Cessation. Role: Co-I, Medical Director
NIH/Fogarty 1RO1TW007944-01 (PI: Nichter) (9/1/07 –8/30/12)
Cessation Research and Training in India and Indonesia
The major purpose of this project is to develop academic-community research partnerships and practice-based
research networks to support tobacco cessation research in India and Indonesia. Role: Co-PI
NCI R21 CA127787 (PI: Muramoto M) (1/1/08 – 12/31/10)
Parents Awareness Reducing Exposure to Nicotine and Tobacco (PARENT)
The major purpose of this project is to develop and pilot test a system intervention for private licensed
childcare centers to reduce second hand smoke exposure for children by influencing parental tobacco use.
Completed Research Support (selected)
AZ Department of Health Services (PI: Muramoto, M) (1/01/2008-12/31/2009)
Arizona Healthcare Cost Containment System (AHCCCS): Interagency Services Agreement # YH08-0072
The major purpose of this project is to provide technical support for the development of AHCCCS’s health
information exchange, clinical and patient decision support tools, e-learning products, and the technical and
social infrastructure needed for AHCCCS and its provider and beneficiary populations to be more involved with
clinical translational research.
NIDDK R34DK072196 (PI: Bassford, T) (7/1/06 - 6/30/09)
Major purpose is to conduct a Phase I pilot feasibility study of a group outpatient visit (GOV) method of
delivering care to a multi-ethnic adult patients with Type II diabetes in a primary care setting.
Role: Co-I responsible for assisting with provider education and design of larger Phase II efficacy trial.
NCI RO1 CA93957 (PI: Muramoto) (9/26/02 – 8/31/08)
Community-based Training Models for Tobacco Cessation
The major purpose of this project is to develop an internet-based tobacco cessation training and conduct a
randomized controlled trial of the internet training compared to a traditional in-person training.
NCI 1R21CA112461-01A1 (PI: Muramoto M) (9/1/05 – 8/31/08)
Brief Tobacco Intervention Training in Childcare Centers
The major purpose of this project is to train childcare center workers to conduct brief tobacco interventions to
reduce second hand smoke exposure for children by influencing parental tobacco use.
NIH/Fogarty R01 TW05969-01 (PI: Lando) (7/1/02 – 6/30/07)
Cessation Research and Training in India and Indonesia
The major purpose of this project is to develop tobacco cessation research capacity of researchers in India and
Indonesia. Role: Co-I
NHLBI R21HL083831 (PI: Ritenbaugh, C) (4/06 – 3/08)
Preventing CVD in Native Populations: The Traditional Living Challenge
Major purpose is to develop and pilot test an immersion “traditional living experience” intervention incorporating
traditional native lifestyles with a focus on diet, physical activity, and tobacco use patterns to promote adoption
of heart healthy lifestyles. Role: Co-I responsible for helping develop tobacco cessation intervention.
Sanofi-Synthelabo, Inc. EFC 4796 (PI: Muramoto) (1/1/03 - 12/31/05)
Clinical Trial. Comparison of the efficacy and safety of 2 oral doses of rimonabant, 5 mg/day or 20 mg/day,
versus placebo, as an aid to maintenance of smoking cessation – a multiple country, randomized, double-blind,
5 arm, placebo-controlled, parallel-group, fixed dose, 2-year, multi-center, Phase III Trial; 1-year treatment,1-
year follow-up. Role: Site PI
Pfizer (PI: Muramoto)
Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study with Follow-Up Evaluating the
Safety and Efficacy of Varenicline Tartrate (CP-526,555) in Comparison to Zyban for Smoking Cessation.
Role: Site PI
NCI 5R01CA77081 (PI: Muramoto) (9/1/97-7/31/05)
Zyban Treatment for Youth Smoking Cessation
This was a randomized double-blind, placebo controlled dose-ranging trial of sustained release bupropion for
smoking cessation in adolescents. Role: PI (Co-I 9/97-6/00)
Robert Wood Johnson Foundation ID 040672 (PI: Muramoto) (10/01/00 – 7/30/04)
Mapping the Natural History of Smoking and Smoking Cessation Among Pregnant Women. A longitudinal
qualitative (ethnographic) and quantitative observational study of the natural history of smoking, smoking
cessation, and relapse in low-income pregnant and postpartum women, examined the impact of depressive
symptoms, social support, social networks, partner interactions, and healthcare provider messages to quit.
NCI 5R01CA77081 (PI: Muramoto) (7/1/00-7/30/05)
Hispanic Youth Recruitment Supplement: Zyban Treatment for Youth Smoking Cessation. Supplemental
project developed and implemented culturally appropriate recruitment strategies for Hispanic youth.
NIDA 5R21DA13121 (PI: Shoham) (9/1/99-9/1/02)
Family consultation for change-resistant smokers (FAMCON). Pilot project developed and tested a family
systems couples’ behavioral counseling intervention for change-resistant, high-risk medically compromised
smokers. Role: Co-I. Responsible for evaluation of subject’s medical risks and individual/couple behavioral
factors for selection of pharmacotherapy to match medical risk/behavioral preferences profile.
Pfizer (PI: Muramoto) (6/1/06-12/31/06)
A phase 3, multi-site, randomized, parallel, head-to-head comparative efficacy study of two experimental
nicotine gums against uncoated nicotine polacrilex gum (4 mg) on the speed to meaningful relief of acute
craving. Major purpose was to compare the efficacy of two experimental nicotine gums with currently
approved nicotine polacrilex gum for relief of acute cigarette craving.
U.S. Department of Defense (PI: Lando) (10/01 - 9/07)
A Model DOD Systems Approach for Tobacco Cessation
Major purpose is to develop and test a systematic intervention of enhancing existing cessation services with
pharmacotherapy and tobacco cessation training to reduce tobacco use prevalence on military bases.
Role: Co-I, PI on Univ. of Ariz. Subcontract. Responsible for development of tobacco cessation skills training
for community members and health providers.